Vorinostat

{
  "id": "MLC-T-ONC-009319",
  "term": "Vorinostat",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat cutaneous T-cell lymphoma that came back, got worse, or did not get better during or after treatment with two systemic therapies. It is also being studied in the treatment of other types of cancer. Vorinostat blocks certain enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase inhibitor. Also called SAHA, suberoylanilide hydroxamic acid, and Zolinza.",
    "A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier."
  ],
  "abbreviation": "SAHA",
  "synonyms": [
    "SAHA",
    "suberoylanilide hydroxamic acid",
    "Zolinza"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/vorinostat/"
}